ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K

ASLAN PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS


-

Interim readout...

Related Keywords

California ,United States ,Singapore ,America ,Carl Firth ,Emma Thompson ,Ashleyr Robinson ,Company Us Securities ,Spurwing Communications ,Linkedin ,Pharmaceuticals Nasdaq ,Company Annual Report On Form ,Commission File No ,Exchange Commission ,Exchange Commission On ,Lifesci Advisors ,Eczema Area Severity Index ,Chief Executive Officer ,North America ,Investigator Global Assessment ,Last Observation Carried Forward ,San Mateo ,Commission File ,Annual Report ,Sci Advisors ,Markets ,